Falk Jeremy A, Kadiev Steven, Criner Gerard J, Scharf Steven M, Minai Omar A, Diaz Philip
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, for the David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Proc Am Thorac Soc. 2008 May 1;5(4):543-8. doi: 10.1513/pats.200708-142ET.
The cardiac manifestations of chronic obstructive pulmonary disease (COPD) are numerous. Impairments of right ventricular dysfunction and pulmonary vascular disease are well known to complicate the clinical course of COPD and correlate inversely with survival. The pathogenesis of pulmonary vascular disease in COPD is likely multifactorial and related to alterations in gas exchange and vascular biology, as well as structural changes of the pulmonary vasculature and mechanical factors. Several modalities currently exist for the assessment of pulmonary vascular disease in COPD, but right heart catheterization remains the gold standard. Although no specific therapy other than oxygen has been generally accepted for the treatment of pulmonary hypertension in this population, there has been renewed interest in specific pulmonary vasodilators. The coexistence of COPD and coronary artery disease occurs frequently. This association is likely related to shared risk factors as well as similar pathogenic mechanisms, such as systemic inflammation. Management strategies for the care of patients with COPD and coronary artery disease are similar to those without COPD, but care must be given to address their respiratory limitations. Arrhythmias occur frequently in patients with COPD, but are rarely fatal and can generally be treated medically. Use of beta-blockers in the management of cardiac disease, while a theoretical concern in patients with increased airway resistance, is generally safe with the use of cardioselective agents.
慢性阻塞性肺疾病(COPD)的心脏表现多种多样。右心室功能障碍和肺血管疾病的损害众所周知,会使COPD的临床病程复杂化,并与生存率呈负相关。COPD中肺血管疾病的发病机制可能是多因素的,与气体交换和血管生物学的改变、肺血管的结构变化以及机械因素有关。目前有几种方法可用于评估COPD中的肺血管疾病,但右心导管检查仍是金标准。虽然除了氧气之外,没有其他特定疗法被普遍接受用于治疗该人群的肺动脉高压,但人们对特定的肺血管扩张剂重新产生了兴趣。COPD与冠状动脉疾病经常并存。这种关联可能与共同的危险因素以及相似的致病机制有关,如全身炎症。COPD和冠状动脉疾病患者的护理管理策略与无COPD患者相似,但必须注意解决他们的呼吸限制问题。心律失常在COPD患者中经常发生,但很少致命,通常可以通过药物治疗。在心脏病管理中使用β受体阻滞剂,虽然理论上对气道阻力增加的患者是一个问题,但使用心脏选择性药物通常是安全的。